Drawing for OLYPIA

USPTO serial 78930624

OLYPIA

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
LAPTER, ALAIN J
Law office
TMEG LAW OFFICE 108 - EXAMINING ATTORNEY ASSIGNED

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with OLYPIA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nadine P. Flynn

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for human useACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 26, 2006MAB1ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT—
Dec 26, 2006ABN1ABANDONMENT - EXPRESS MAILED—
Dec 26, 2006EXARTEAS EXPRESS ABANDONMENT RECEIVED—
Dec 15, 2006CPRAPRIORITY ACTION MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Dec 15, 2006CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Dec 13, 2006DOCKASSIGNED TO EXAMINER—
Jul 21, 2006NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance